Patient-derived Organoids (tumoroids)  

Perform initital screening tests using InnoSer’s in vitro immuno-oncology assays to select your lead candidate compounds and progress to in vivo studies with confidence   

Home » Oncology CRO Services » Patient-derived Organoids (tumoroids)

Patient-derived organoids (tumoroids) represent a complex 3D in vitro organoid (tumoroid) culture system established from resected tumor samples obtained from oncologic patients. Preserving the tumor and patient heterogeneity, patient-derived organoids (tumoroids) represent a powerful tool to screen multiple lead compounds to understand patient-specific drug responses.   

Therefore, high-throughput in vitro assays carried out using patient-derived organoids (tumoroids) are highly relevant for a variety of therapies. Compared to immuno-oncology in vitro assays using cancer-associated rodent or human cell lines, patient-derived organoids (tumoroids) better represent patient heterogeneity.

Accordingly, in combination with InnoSer’s patient-derived xenograft (PDX) models, that can be studied in immunodeficient or humanized mouse models, this approach provides you with seamless access from in vitro to in vivo testing using the same parental tumor samples. 

Developing new, safe, and efficacious anticancer therapies is an extremely intricate process. As a preclinical oncology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.  

Scientists at InnoSer collaborate with you to develop the most optimal study design to help answer your research questions in the most cost-effective way. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo oncology drug development portfolio. 

Services with patient-derived organoids (tumoroids) that InnoSer offers:  

  • Wide range of cancer types available.
  • High-throughput drug screening capabilities.
  • Well-characterized parental tumor samples (RNA seq, hot spot mutations, histopathology).
  • Access to snap frozen and PFA preserved samples for additional testing.  

Find the right model for you.

Compare our model capabilities and discover which of our oncology platforms suits your research needs

oncology leaflet download

Key patient-derived organoids (tumoroids) assays:

Test the efficacy of your treatments with the following readouts: 

  • High-throughput drug screening  
  • Widefield and confocal live cell imaging 

Related model options

Oncology Platform Overview

Highly relevant oncology CRO services to facilitate preclinical drug development.

Immuno-Oncology in vitro Assays

InnoSer offers oncology CRO services using cancer-associated tumor and microenvironment-associated cell lines (human and rodent).

Cell line-derived Xenograft (CDX) Mouse Models

CDX models represent one of the first steps to evaluate the efficacy using in vivo models of human cancer.

AAALAC Accreditation

InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.


Animal Welfare

The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

Need more information?

If you have any questions about how we can help accelerate your research,

then let us know